title: Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.
abstract: Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rationale to avoid an MS inflammatory resurgence. The JC virus index value may also provide further useful information to help practitioners and patients in their decision process.
authors.affiliation: Neurology Department and Stroke-Unit, F. Mitterrand Hospital, Pau, France. Electronic address: bruno.barroso@ch-pau.fr.
authors.forename: Bruno
authors.initials: B
authors.lastname: Barroso
authors.affiliation: Neurology Department and Stroke-Unit, F. Mitterrand Hospital, Pau, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Miquel
authors.affiliation: Neurology Department and Stroke-Unit, F. Mitterrand Hospital, Pau, France.
authors.forename: Raluca
authors.initials: R
authors.lastname: Marasescu
authors.affiliation: Neurology Department and Stroke-Unit, F. Mitterrand Hospital, Pau, France.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Demasles
authors.affiliation: Neurology Department and Stroke-Unit, F. Mitterrand Hospital, Pau, France.
authors.forename: Elsa
authors.initials: E
authors.lastname: Krim
authors.affiliation: Neurology Department and Stroke-Unit, F. Mitterrand Hospital, Pau, France.
authors.forename: Mikael
authors.initials: M
authors.lastname: Bonnan
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007577:JC Virus / Q000276:immunology; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D000069442:Natalizumab / Q000627:therapeutic use*; D019233:Retreatment
chemical_list: D000914:Antibodies, Viral; D007155:Immunologic Factors; D000069442:Natalizumab
keywords: Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy